Immunoglobulin - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

Market Report | 2025-07-02 | 125 pages | Mordor Intelligence

AVAILABLE LICENSES:

- Single User License $4750.00
- Team License (1-7 Users) $5250.00
- Site License $6500.00
- Corporate License $8750.00

Report description:

Immunoglobulin Market Analysis

The immunoglobulin market stands at USD 17.27 billion in 2025 and is projected to expand to USD 24.08 billion by 2030, registering a 6.87% CAGR. Robust growth reflects widening use of plasma-derived and recombinant immunoglobulin therapies for primary immunodeficiency diseases (PID), chronic inflammatory demyelinating polyneuropathy (CIDP), and several hematological and neurological disorders. IgG formulations dominate because of their long half-life and broad clinical utility, while IgM and subcutaneous products are advancing fastest as manufacturers refine purification processes and develop high-concentration 20% solutions. Demand strength is amplified by sustained investments that lift global plasma-fractionation capacity, increasing clinical adoption in Asia-Pacific, and the shift to home-based care models that favor subcutaneous self-administration. On the supply side, structural barriers such as donor-eligibility rules, cold-chain logistics, and high capital costs reinforce the competitive positions of integrated producers.

Global Immunoglobulin Market Trends and Insights

Rising prevalence of PID

Global PID diagnosis has climbed to roughly 1 in 1,200 live births, propelled by wider genetic testing and stronger clinical awareness. Substantial unmet need remains: pooled analyses show 67.7% pneumonia prevalence among common variable immunodeficiency patients and 59.0% upper-respiratory infection prevalence, emphasizing the indispensable role of lifelong IgG replacement. Rising detection rates in developing regions are unlocking new patient pools, while health-economic data indicate hospitalizations for severe infections average USD 122,739-heightening payer incentives for prophylactic immunoglobulin therapy. Consequently, the immunoglobulin market enjoys durable demand as health systems shift toward prevention.

Growing IVIG use in neurology (CIDP)

Seventy-six percent of treatment-naive CIDP patients improve clinically after IVIG therapy. FDA approval of GAMMAGARD LIQUID for adults with CIDP in 2024 legitimized immunoglobulin as a front-line neurological therapy. Long-term studies confirm stable strength and motor function when patients transition from intravenous to subcutaneous dosing; 16 of 17 patients preferred home-based regimens. Expanded neurological protocols widen revenue streams and reinforce product pipelines.

High therapy cost & reimbursement gaps

Median IVIG spend sits at USD 133,334 over two years for CIDP, dwarfing USD 3,101 for steroid-only care. Insurance coverage can require stringent diagnostic proof, delaying therapy initiation. Global price disparities compel physicians in low-income regions to ration doses, potentially limiting the immunoglobulin market's full addressable population.

Other drivers and restraints analyzed in the detailed report include:

Expanded plasma-fractionation capacity / Emerging recombinant/plant-based Ig platforms / Stringent donor-screening regulations /

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

IgG led with 68.45% immunoglobulin market share in 2024 due to its pharmacokinetic advantages and broad label coverage. IgM's 7.35% CAGR signals rising clinical acceptance for early-stage infection management and oncological indications. Yield-enhancement protocols-such as ADMA Biologics' FDA-filed supplement-promise a 20% uptick in IgG output, which may ease cost pressures. IgA therapies target mucosal immunity for selective deficiencies, while niche IgE products serve severe allergic conditions. Methodologies that achieve 95% purity and 90% yield in IgG through bathophenanthroline complexes underscore ongoing process intensification, underpinning sustained leadership of IgG in the immunoglobulin market.

Second-generation chromatography resins and improved virus-inactivation steps also benefit IgM by delivering greater consistency, fueling the fastest segment growth. Research into IgD's immunoregulatory role could eventually seed new subsegments, although commercial relevance remains nascent. Across all classes, tighter pharmacovigilance and post-marketing surveillance support broader payer acceptance and facilitate life-cycle extensions such as higher-concentration or co-formulated options.

The Immunoglobulin Market Report is Segmented by Product (IgG, Iga, Igm, Ige, Igd), Mode of Delivery (Intravenous, Subcutaneous, Intramuscular), Application (Hypogammaglobulinemia, CIDP, Primary Immunodeficiency Disease, Myasthenia Gravis, ITP, Other Applications), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Geography Analysis

North America commanded 44.31% of the immunoglobulin market in 2024, reflecting dense plasma-collection infrastructure, clear

Medicare reimbursement, and rapid uptake of subcutaneous formulations. The United States alone hosted over 1,000 plasma centers in 2025, ensuring domestic supply resiliency even as donor-screening rules tighten. CSL Behring's 15% sales surge in the first half of 2025 validated persistent clinical demand. Policy momentum-such as bipartisan support for the Plasma Donation Modernization Act-should further streamline donor recruitment.

Asia-Pacific is the fastest-expanding region at 7.49% CAGR. Indonesia's forthcoming Karawang fractionator will lessen import reliance, while Japan sponsors region-specific studies of Takeda's subcutaneous TAK-771 to address local PID populations. China's environment is shifting as CSL divests Wuhan assets, creating entry points for domestic plasma players. Broader insurance coverage in South Korea and rising private-sector hospitals in India combine with a growing middle class to swell patient volumes, driving upward momentum for the immunoglobulin market.

Europe exhibits steady, policy-anchored growth. Biotest's EUR 300 million expansion to 1.4 million L and Grifols' pan-European rollout of XEMBIFY exemplify commitment to both capacity and product innovation. Sustainability metrics, such as Grifols' 70-point CSA score, resonate with European Union green ambitions, encouraging cold-chain optimization and lower-carbon packaging. While Middle East and Africa remain smaller today, Gulf Cooperation Council investment in specialty care anchors future demand, and South America's nascent fractionation projects may shorten supply lines over the next decade.

List of Companies Covered in this Report:

CSL Behring / Grifols / Takeda Pharmaceutical Co. / Octapharma / Kedrion Biopharma / Baxter / Bio Products Laboratory (BPL) / LFB Group / ADMA Biologics / China Biologic Products / Biotest / Emergent Bio Solutions / Sanquin / Kamada Ltd. / GC Biopharma / Sichuan Yuanda Shuyang Pharma / Kedrion Biopharma / Pfizer / AbbVie (Orchard Tx) / Argenx SE /

Additional Benefits:

The market estimate (ME) sheet in Excel format /
3 months of analyst support /

Table of Contents:

5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America

6 Competitive Landscape
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Products, and Recent Developments)
6.3.1 CSL Behring
6.3.2 Grifols S.A.
6.3.3 Takeda Pharmaceutical Co.
6.3.4 Octapharma AG
6.3.5 Kedrion Biopharma
6.3.6 Baxter International Inc.
6.3.7 Bio Products Laboratory (BPL)
6.3.8 LFB Group
6.3.9 ADMA Biologics
6.3.10 China Biologic Products
6.3.11 Biotest AG
6.3.12 Emergent BioSolutions
6.3.13 Sanquin
6.3.14 Kamada Ltd.
6.3.15 GC Pharma
6.3.16 Sichuan Yuanda Shuyang Pharma
6.3.17 Kedrion Biopharma
6.3.18 Pfizer Inc.
6.3.19 AbbVie (Orchard Tx)
6.3.20 Argenx SE

7 Market Opportunities & Future Outlook
7.1 White-space & Unmet-need Assessment

Immunoglobulin - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

Market Report | 2025-07-02 | 125 pages | Mordor Intelligence

To place an Order with Scotts International:
- - Print this form
- - Complete the relevant blank fields and sign
- - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	$4750.00
	Team License (1-7 Users)	$5250.00
	Site License	$6500.00
	Corporate License	$8750.00
	VAT	
	Total	

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.
** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*		Phone*	
First Name*		Last Name*	
Job title*			
Company Name*		EU Vat / Tax ID / NIP number*	
Address*		City*	
Zip Code*		Country*	
		Date	2026-03-02
		Signature	

Scotts International. EU Vat number: PL 6772247784
tel. 0048 603 394 346 e-mail: support@scotts-international.com
www.scotts-international.com